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MIC50a b s t r a c t
Ethionamide (ETH) is an important second-line antituberculosis drug used for the treatment of patients
infected with multidrug-resistant Mycobacterium tuberculosis. Recently, we reported that the loading of
ETH into thermally carbonized-porous silicon (TCPSi) nanoparticles enhanced the solubility and perme-
ability of ETH at different pH-values and also increased its metabolization process. Based on these results,
we synthesized carboxylic acid functionalized thermally hydrocarbonized porous silicon nanoparticles
(UnTHCPSi NPs) conjugated with ETH and its antimicrobial effect was evaluated against Mycobacterium
tuberculosis strain H37Rv. The activity of the conjugate was increased when compared to free-ETH, which
suggests that the nature of the synergy between the NPs and ETH is likely due to the weakening of the
bacterial cell wall that improves conjugate-penetration. These ETH-conjugated NPs have great potential
in reducing dosing frequency of ETH in the treatment of multidrug-resistant tuberculosis (MDR-TB).
 2016 Elsevier Ltd. All rights reserved.Tuberculosis (TB) remains a leading cause of death from infec-
tious diseases worldwide. In 2014, 9.6 million people were esti-
mated to have developed active TB and 1.5 million died from the
disease, according to the World Health Organization (WHO)
report.1 Adding to this, there has been an increase in the global
TB incidence among individuals infected with HIV. From the
9.6 million new cases reported in 2014, 12% were HIV-positive.1
The emergence of multidrug-resistant (MDR) TB, defined by
resistance to both rifampicin (RIF) and isoniazid (INH), also repre-
sents a major public health concern in the control of the disease.
Indeed, it has been estimated that 480,000 patients developed
MDR-TB in 2014.2 Given the limited knowledge on relevant mech-
anisms of drug resistance in TB,3 it is urgent to develop new strate-
gies to improve the bioavailability of anti-TB drugs.
The most effective first-line antibiotics for the treatment of TB
include rifampicin and INH.4 One of the most widely used sec-
ond-line drugs for the treatment of MDR-TB is ethionamide
(Scheme 1, ETH, 1), which is a thioamide antibiotic structurally
similar to INH. The mode of action of the activated form of
ETH is via inhibition of the InhA gene product, enoyl-ACP reduc-tase,5–7 the same target of INH.5 ETH is activated by a KatG-inde-
pendent mechanism5 and the major metabolite in vivo is its
S-oxide.8,9
The active form of ETH create adducts with nicotinamide ade-
nine dinucleotide (NAD) that inhibit the inhA enzyme5 and, conse-
quently, induces disorders on mycolic acid synthesis. Studies both
in mammals and bacteria suggest that ETH-SO retains the biologi-
cal activity of the parent drug,10 which is in line with the fact that,
ETH and many current antimycobacterial agents, require some
form of cellular activation corresponding to the oxidative, reduc-
tive, or hydrolytic unmasking of active groups.11–13 Other metabo-
lites for ETH, such as ETH-nitrite, ETH-aldehyde and ETH-OH, have
been identified, although with less therapeutic importance.14–18
Recently, we reported the solubility, toxicity, permeability, and
metabolic profiles of thermally carbonized-porous silicon (TCPSi)
microparticles loaded with ETH. The solubility and permeability
of ETH was clearly enhanced after being loaded into TCPSi particles
at different pH-values and showed a fast metabolization process in
the presence of the TCPSi particles.19 Based on these promising
results, we synthesized carboxylic acid functionalized thermally
hydrocarbonized porous silicon nanoparticles (UnTHCPSi NPs)
conjugated with ETH20–22 and evaluated the antimicrobial effect
of this conjugate against M. tuberculosis strain H37Rv,23 the most
Scheme 1. Structure of ethionamide (ETH)
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laboratory settings.
Delivery systems using PSi nanoparticles (NPs) are known to be
superior than microparticles, because they enhance the interac-
tions with the cells and can be uptaken in high extents.24–26 The
high drug bioavailabilities of PSi NPs may also result in drug pro-
tection and controlled drug release when the nanocarriers are
exposed to the circulation.24–26
For the synthesis of the UnTHCPSi NPs, monocrystalline boron
doped p+ Si h100i wafers with a resistivity of 0.01–0.02Xcm were
electrochemically anodized in a 1:1 (v/v) hydrofluoric acid (38%)-
ethanol electrolyte, pulsed with low and high current density etch-
ing profiles to fracture the surface of Si wafers at different inter-
vals. After that, the etching current was increased to the
electropolishing region to lift off the obtained multilayer film from
the substrate. The membranes were dried and set under N2 flow
(1 L/min) for 30 min at room temperature to eliminate oxygen
and residual moisture. Then, at room temperature, acetylene
(C2H2) flow (1 L/min) was added to the N2 flow for 15 min before
enhancing the temperature for 15 min to 500 C under the 1:1
(v/v) N2/C2H2 flow. The THCPSi films were then allowed to cool
down to room temperature under N2 flow and further treated by
immersion in undecylenic acid for 16 h at 120 C to provide a car-
boxyl functionalization (UnTHCPSi). The NPs were made by ball
milling the UnTHCPSi films in 10 vol-% undecylenic acid-decane
solution.21,22Table 1
Size, PdI, f-potential of the NPs before and after the ETH conjugation. Results are
presented as mean ± SD (nP 3).




UnTHCPSi 175.91 ± 0.16 0.09 ± 0.12 25.50 ± 0.16
UnTHCPSi-ETH 183.82 ± 0.15 0.07 ± 0.16 10.00 ± 0.15
Fig. 1. Attenuated total reflection-FTIR spectra of UnTHCPSi NPs (A), ETH (B), and
UnTHCPSi-ETH NPs (C). The acquired spectrum for the ETH-conjugated NPs
confirmed the chemical conjugation of ETH onto the PSi NPsFabrication of NPs with great stability and security, plummy
drug release profiles and useful cellular uptake still represent the
main challenges for the progress of NPs with high potential to beETH (µg/ml)













Fig. 2. Evaluation of the antimicrobial effect againstM. tuberculosis H37Rv. Cultures
of M. tuberculosis H37Rv were incubated with increasing concentrations of INH (A),
ETH (B) or UnTHCPSi-ETH (C). After 7 days of incubation, CFU were performed to
determine the bacterial viability. Following ASTM guidelines, the reported value for
the limit of detection for microbiological purposes should be ‘‘less than the dilution
value” if no colonies are recovered; therefore, the limit of detection for our
experiments is 1 log10 CFU/mL. All countable colonies, even those below the
countable range, were counted and reported as an estimated count. The minimal
inhibitory concentration (MIC) of each drug was determined as the lowest
concentration of antibiotic that inhibits the growth of a microorganism
N. Vale et al. / Bioorganic & Medicinal Chemistry Letters 27 (2017) 403–405 405applied in nanomedicine. Nevertheless, we have recently pub-
lished promising results on the potential of the UnTHCPSi NPs for
drug delivery.20–22 In the present study, 1-ethyl-3-(3-dimethy-
laminopropyl)carbodiimide (EDC)/N-Hydroxysuccinimide (NHS)
coupling chemistry was used to conjugate ETH to the surface of
bare particles in an aqueous solution (Table 1 and Fig. 1).27 To func-
tionalize the surface of the particles with ETH, the carboxyl groups
of the NPs were activated and covalently conjugated to the amine
groups of ETH to form UnTHCPSi-ETH nanocomposites.27
We also set out to compare the in vitro antimicrobial effect of
UnTHCPSi-ETH and bare UnTHCPSi against M. tuberculosis H37Rv
(Trudeau Institute Mycobacterial Collection; Fig. 2).28
The antimicrobial effects of the compounds were determined
using an adapted version of the protocol described by Martin
et al.27 Briefly, a serial of 2-fold dilutions of the test material
(ETH; encapsulated ETH; and the broad-spectrum antibiotic INH
as a positive control) were performed. To each well 5  105 CFU
of M. tuberculosis H37Rv was added and the plates were incubated
at 37 C for 7 days. A serial of 10-fold dilutions of the suspensions
were plated on nutrient 7H11 and bacterial colony counts were
performed after 3 weeks of incubation at 37 C.
As shown in Fig. 2, INH required lower concentrations to inhibit
bacterial growth by half (Fig. 2A, IC50: 0.08066 lg/mL) when com-
pared to ETH (Fig. 2C, IC50: 4.920 lg/mL) and UnTHCPSi-ETH
(Fig. 2B, IC50: 4.785 lg/mL). ETH shows better bacterial growth
inhibition at the concentration range of 0.5–5 lg/mL and this is
comparable to a recent study, in that growth of M. tuberculosis
H37Rv at different concentrations of ETH were tested, and the best
profile was ranging between 0.31 and 5.0 lg/mL.29 Interestingly,
within the range of concentrations tested, ETH alone was not able
to completely inhibit M. tuberculosis growth, as observed in the
presence of UnTHCPSi-ETH. These results suggest that the nature
of the ETH-loaded NPs synergy is likely due to the weakening of
the bacterial cell wall that improves the conjugate penetration.
Our in vitro results justify the study of this conjugate in animal
models of TB in order to establish whether the antimicrobial effect
of the UnTHCPSi-ETH also occurs in vivo.
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